Less-than-Brilinta performance in US could be due to aspirin
This article was originally published in Scrip
Executive Summary
Aspirin could be responsible for ticagrelor (AstraZeneca's Brilinta/Brilique) having less of an effect in North America than in the rest of the world, suggests a new analysis of the pivotal PLATO study published online in the journal Circulation (27 June).